MersV1, Ncbi, Merge, bibRecord, 001830

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Identifieur interne : 001830 ( Ncbi/Merge ); précédent : 001829; suivant : 001831

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Auteurs : Christoph Wirblich [États-Unis] ; Christopher M. Coleman [États-Unis] ; Drishya Kurup [États-Unis] ; Tara S. Abraham [États-Unis] ; John G. Bernbaum [États-Unis] ; Peter B. Jahrling [États-Unis] ; Lisa E. Hensley [États-Unis] ; Reed F. Johnson [États-Unis] ; Matthew B. Frieman [États-Unis] ; Matthias J. Schnell [États-Unis]

Source :

Journal of virology [ 1098-5514 ] ; 2017.

RBID : pubmed:27807241

Descripteurs français

English descriptors

KwdEn :
- Animals, Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Cross Protection (immunology), Disease Models, Animal, Gene Expression Regulation, Viral, Humans, Immunization, Mice, Microbial Interactions, Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (immunology), Rabies (immunology), Rabies (prevention & control), Rabies (virology), Rabies virus (genetics), Rabies virus (immunology), Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Vaccines, Attenuated, Vaccines, Synthetic, Viral Proteins (genetics), Viral Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (adverse effects), Viral Vaccines (genetics), Viral Vaccines (immunology), Virus Assembly.
MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , adverse effects : Viral Vaccines.
- chemical , genetics : Recombinant Fusion Proteins, Spike Glycoprotein, Coronavirus, Viral Proteins, Viral Vaccines.
- genetics : Middle East Respiratory Syndrome Coronavirus, Rabies virus.
- immunology : Coronavirus Infections, Cross Protection, Middle East Respiratory Syndrome Coronavirus, Rabies, Rabies virus, Recombinant Fusion Proteins, Spike Glycoprotein, Coronavirus, Viral Proteins, Viral Vaccines.
- prevention & control : Coronavirus Infections, Rabies.
- virology : Coronavirus Infections, Rabies.
- Animals, Disease Models, Animal, Gene Expression Regulation, Viral, Humans, Immunization, Mice, Microbial Interactions, Vaccines, Attenuated, Vaccines, Synthetic, Virus Assembly.

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic.

DOI: 10.1128/JVI.02040-16
PubMed: 27807241

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000F08
to stream PubMed, to step Curation: 000F08
to stream PubMed, to step Checkpoint: 000B87

Links to Exploration step

pubmed:27807241

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.</title>
<author><name sortKey="Wirblich, Christoph" sort="Wirblich, Christoph" uniqKey="Wirblich C" first="Christoph" last="Wirblich">Christoph Wirblich</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurup, Drishya" sort="Kurup, Drishya" uniqKey="Kurup D" first="Drishya" last="Kurup">Drishya Kurup</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abraham, Tara S" sort="Abraham, Tara S" uniqKey="Abraham T" first="Tara S" last="Abraham">Tara S. Abraham</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bernbaum, John G" sort="Bernbaum, John G" uniqKey="Bernbaum J" first="John G" last="Bernbaum">John G. Bernbaum</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F" last="Johnson">Reed F. Johnson</name>
<affiliation wicri:level="2"><nlm:affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schnell, Matthias J" sort="Schnell, Matthias J" uniqKey="Schnell M" first="Matthias J" last="Schnell">Matthias J. Schnell</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA Matthias.Schnell@jefferson.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27807241</idno>
<idno type="pmid">27807241</idno>
<idno type="doi">10.1128/JVI.02040-16</idno>
<idno type="wicri:Area/PubMed/Corpus">000F08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F08</idno>
<idno type="wicri:Area/PubMed/Curation">000F08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F08</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B87</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B87</idno>
<idno type="wicri:Area/Ncbi/Merge">001830</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.</title>
<author><name sortKey="Wirblich, Christoph" sort="Wirblich, Christoph" uniqKey="Wirblich C" first="Christoph" last="Wirblich">Christoph Wirblich</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurup, Drishya" sort="Kurup, Drishya" uniqKey="Kurup D" first="Drishya" last="Kurup">Drishya Kurup</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abraham, Tara S" sort="Abraham, Tara S" uniqKey="Abraham T" first="Tara S" last="Abraham">Tara S. Abraham</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bernbaum, John G" sort="Bernbaum, John G" uniqKey="Bernbaum J" first="John G" last="Bernbaum">John G. Bernbaum</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F" last="Johnson">Reed F. Johnson</name>
<affiliation wicri:level="2"><nlm:affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schnell, Matthias J" sort="Schnell, Matthias J" uniqKey="Schnell M" first="Matthias J" last="Schnell">Matthias J. Schnell</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA Matthias.Schnell@jefferson.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cross Protection (immunology)</term>
<term>Disease Models, Animal</term>
<term>Gene Expression Regulation, Viral</term>
<term>Humans</term>
<term>Immunization</term>
<term>Mice</term>
<term>Microbial Interactions</term>
<term>Middle East Respiratory Syndrome Coronavirus (genetics)</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Rabies (immunology)</term>
<term>Rabies (prevention & control)</term>
<term>Rabies (virology)</term>
<term>Rabies virus (genetics)</term>
<term>Rabies virus (immunology)</term>
<term>Recombinant Fusion Proteins (genetics)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (genetics)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Synthetic</term>
<term>Viral Proteins (genetics)</term>
<term>Viral Proteins (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (adverse effects)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
<term>Virus Assembly</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Assemblage viral</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Immunisation</term>
<term>Infections à coronavirus ()</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Interactions microbiennes</term>
<term>Modèles animaux de maladie humaine</term>
<term>Protection croisée (immunologie)</term>
<term>Protéines de fusion recombinantes (génétique)</term>
<term>Protéines de fusion recombinantes (immunologie)</term>
<term>Protéines virales (génétique)</term>
<term>Protéines virales (immunologie)</term>
<term>Rage (maladie) ()</term>
<term>Rage (maladie) (immunologie)</term>
<term>Rage (maladie) (virologie)</term>
<term>Régulation de l'expression des gènes viraux</term>
<term>Souris</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (effets indésirables)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins atténués</term>
<term>Vaccins synthétiques</term>
<term>Virus de la rage (génétique)</term>
<term>Virus de la rage (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Recombinant Fusion Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Rabies virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines de fusion recombinantes</term>
<term>Protéines virales</term>
<term>Vaccins antiviraux</term>
<term>Virus de la rage</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Infections à coronavirus</term>
<term>Protection croisée</term>
<term>Protéines de fusion recombinantes</term>
<term>Protéines virales</term>
<term>Rage (maladie)</term>
<term>Vaccins antiviraux</term>
<term>Virus de la rage</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cross Protection</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Rabies</term>
<term>Rabies virus</term>
<term>Recombinant Fusion Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Rabies</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Rage (maladie)</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Rabies</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Gene Expression Regulation, Viral</term>
<term>Humans</term>
<term>Immunization</term>
<term>Mice</term>
<term>Microbial Interactions</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Synthetic</term>
<term>Virus Assembly</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Assemblage viral</term>
<term>Humains</term>
<term>Immunisation</term>
<term>Infections à coronavirus</term>
<term>Interactions microbiennes</term>
<term>Modèles animaux de maladie humaine</term>
<term>Rage (maladie)</term>
<term>Régulation de l'expression des gènes viraux</term>
<term>Souris</term>
<term>Vaccins atténués</term>
<term>Vaccins synthétiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27807241</PMID>
<DateCompleted><Year>2017</Year>
<Month>05</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>91</Volume>
<Issue>2</Issue>
<PubDate><Year>2017</Year>
<Month>Jan</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e02040-16</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02040-16</ELocationID>
<Abstract><AbstractText>Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Rabies virus-based vectors have been proven to be efficient dual vaccines against rabies and emergent infectious diseases such as Ebola virus. Here we show that inactivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses against MERS-CoV and RABV. This novel vaccine is easy to produce and may be useful to protect target animals, such as camels, as well as humans from deadly MERS-CoV and RABV infections. Our results indicate that this vaccine approach can prevent disease, and the RABV-based vaccine platform may be a valuable tool for timely vaccine development against emerging infectious diseases.</AbstractText>
<CopyrightInformation>Copyright © 2017 American Society for Microbiology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wirblich</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coleman</LastName>
<ForeName>Christopher M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kurup</LastName>
<ForeName>Drishya</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Abraham</LastName>
<ForeName>Tara S</ForeName>
<Initials>TS</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bernbaum</LastName>
<ForeName>John G</ForeName>
<Initials>JG</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jahrling</LastName>
<ForeName>Peter B</ForeName>
<Initials>PB</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hensley</LastName>
<ForeName>Lisa E</ForeName>
<Initials>LE</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Johnson</LastName>
<ForeName>Reed F</ForeName>
<Initials>RF</Initials>
<AffiliationInfo><Affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Frieman</LastName>
<ForeName>Matthew B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schnell</LastName>
<ForeName>Matthias J</ForeName>
<Initials>MJ</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-9040-9405</Identifier>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA Matthias.Schnell@jefferson.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Jefferson Vaccine Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>HHSN272200700016I</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA056036</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI095569</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI105204</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>01</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015967" MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056265" MajorTopicYN="N">Microbial Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011818" MajorTopicYN="N">Rabies</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011820" MajorTopicYN="N">Rabies virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019065" MajorTopicYN="N">Virus Assembly</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">coronavirus</Keyword>
<Keyword MajorTopicYN="Y">immunization</Keyword>
<Keyword MajorTopicYN="Y">rabies</Keyword>
<Keyword MajorTopicYN="Y">rhabdovirus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>10</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>10</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>5</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27807241</ArticleId>
<ArticleId IdType="pii">JVI.02040-16</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.02040-16</ArticleId>
<ArticleId IdType="pmc">PMC5215356</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2008 Mar;82(6):2765-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2014 Dec;27(10):543-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25387086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Oct 15;279(42):43661-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15304515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 Jun 25;20(25):1-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26132766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Sep;87(17):9939-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23824801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Jun 3;34(26):2982-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27083424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2013 Feb;187(2):264-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23201293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367 (19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2015 May;479-480:331-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25702088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Oct 2;371(14 ):1360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25271614</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1990 Apr;175(2):485-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2139267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2013 Oct;19(10 ):1313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2016 Mar;186(3):652-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26857507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Oct 21;32(46):6170-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25240756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Oct 2;371(14 ):1359-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25271615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2006;581:271-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17037541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Jan;77(1):237-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12477829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013 Jun 13;18(24):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23787162</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Dec 2;31(49):5897-902</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24120673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther Methods Clin Dev. 2014 Oct 01;1:14046</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26015984</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2014 Dec;29:299-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25461234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Oct 03;8(10):e76469</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24098509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2002 Jan 5;292(1):24-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11878905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26063224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Methods. 2012 Jul;9(7):671-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22930834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 2007 Jan 10;318(1-2):1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17166510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2012 Jan;179(1):166-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22080853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24062443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2013 Sep 10;4(5):e00650-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24023385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2014 Feb;95(Pt 2):408-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24197535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Oct;85(20):10605-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21849459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 2016;96:245-286</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27712626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Biol Ther. 2015 ;15(11):1647-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26414077</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Apr 18;368(16):1560-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23550601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Aug 29;369(9):884-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23923992</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2013;9(5):e1003389</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23737747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Oct;77(20):10889-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14512539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2006 Sep 30;353(2):344-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16820183</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2013 Oct 4;88(40):435-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24159666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 May 30;32(26):3169-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3544-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10706640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dev Ctries. 2015 Jul 04;9(6):543-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26142661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2015 Oct;15(10):1156-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26248510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Pathol. 2016 May;53(3):521-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26869154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Sep 21;30(43):6136-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22884661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Jan;89(1):144-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25320306</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2014 Nov 06;10(11):e1004502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25375324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Oct 14;32(45):5975-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Biol (Basel). 2004;119:185-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15747421</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Protoc Microbiol. 2015 May 01;37:15E.2.1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26344219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2012 Dec 5;434(1):18-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22889613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Dec;77(23):12782-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14610200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Jun;87(12):6551-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23576515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2015 Oct 29;11(10):e1005215</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26513244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pathog Dis. 2014 Jul;71(2):121-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24585737</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Wirblich, Christoph" sort="Wirblich, Christoph" uniqKey="Wirblich C" first="Christoph" last="Wirblich">Christoph Wirblich</name>
</region>
<name sortKey="Abraham, Tara S" sort="Abraham, Tara S" uniqKey="Abraham T" first="Tara S" last="Abraham">Tara S. Abraham</name>
<name sortKey="Bernbaum, John G" sort="Bernbaum, John G" uniqKey="Bernbaum J" first="John G" last="Bernbaum">John G. Bernbaum</name>
<name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name>
<name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name>
<name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F" last="Johnson">Reed F. Johnson</name>
<name sortKey="Kurup, Drishya" sort="Kurup, Drishya" uniqKey="Kurup D" first="Drishya" last="Kurup">Drishya Kurup</name>
<name sortKey="Schnell, Matthias J" sort="Schnell, Matthias J" uniqKey="Schnell M" first="Matthias J" last="Schnell">Matthias J. Schnell</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001830 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001830 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:27807241
   |texte=   One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:27807241" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki